SCHEMBL22816396

SCHEMBL22816396

O=C(O)c1[nH]nnc1OC1CCc2ccccc2C1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 19/20 0.43
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29514738 1.00 HAO1 (0.43) HAO1HTR2CSLC6A4HTR2B
Trifluoroacetic Acid SCHEMBL22608164 0.93 HAO1 (0.39) HAO1
Trifluoroacetic Acid SCHEMBL29490726 0.93 HAO1 (0.39) HAO1
SCHEMBL22807327 0.83 HAO1 (0.38) HAO1
SCHEMBL22807350 0.83 HAO1 (0.38) HAO1
SCHEMBL22807328 0.83 HAO1 (0.38) HAO1
SCHEMBL22608291 0.83 HAO1 (0.39) HAO1
SCHEMBL22608165 0.82 HTR2C (0.34) HTR2CSLC6A4HTR2B
Trifluoroacetic Acid SCHEMBL22608314 0.78 HAO1 (0.35) HAO1
SCHEMBL22816435 0.75 HCAR2 (0.39) HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117126152-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
CN-114258390-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2022-03-29 CN disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
CN-111788187-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2020-10-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885HTR2C 4184/4885SLC6A4 1967/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885HTR2C 4184/4885SLC6A4 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.